Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038883 · ClinicalTrials.gov registry record · NA
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT00038883: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT00038883 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038883, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.
Interventions
- DRUG Campath-1H
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2001-04-09 |
| Est. Completion | 2006-05 |
| Phase | NA |
Why NCT00038883 stopped before completion
NCT00038883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Campath-1H is the first listed.
NCT00038883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00038883 about?
NCT00038883 is a clinical study titled "Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies". High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive...
What is the current status of trial NCT00038883?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2001-04-09. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00038883?
The interventions under investigation include: Campath-1H (DRUG).
Who is sponsoring clinical trial NCT00038883?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00038883's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI